TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25532493

Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 130

Group type: COMPARATOR
Intervention: HP-guided anesthesia
Number of subjects: 130
Study: 23620930

Group type: EXPERIMENTAL
Intervention: Flying needling therapy
Number of subjects: 315

Group type: COMPARATOR
Intervention: Estazolam
Number of subjects: 315

Group type: COMPARATOR
Intervention: Non-acupoint acupuncture
Number of subjects: 315
Study: 21073330

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 52
Study: 19125236

Group type: EXPERIMENTAL
Intervention: BAC 0.02%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BAC 0.05%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BAC 0.08%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BAC 0.10%
Number of subjects: 32

Group type: COMPARATOR
Intervention: Alcohol-placebo
Number of subjects: 32
Study: 16953374

Group type: EXPERIMENTAL
Intervention: Digital X-ray radiogrammetry (DXR)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Quantitative ultrasound (QUS)
Number of subjects: 161
Study: 15073402

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg 3 times daily
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 132
Study: 11458482

Group type: EXPERIMENTAL
Intervention: Active multiprofessional risk factor intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study: 10234673

Group type: EXPERIMENTAL
Intervention: Rest + GTN tetrofosmin imaging
Number of subjects: 30
Study: 8790654

Group type: EXPERIMENTAL
Intervention: Brief advice during one consultation supplemented by a self-help booklet
Number of subjects: 105

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 105
Study: 2568247

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at bedtime
Number of subjects: 195

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice a day
Number of subjects: 195
Study: 1242823

Group type: EXPERIMENTAL
Intervention: Masteril (drostanolone propionate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oophorectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Durabolin (nandrolone phenylpropionate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oestrogens (ethinyl oestradiol)
Number of subjects: 0
Study: 31914075

Group type: EXPERIMENTAL
Intervention: Mosapride citrate with a split-dose of PEG plus ascorbic acid
Number of subjects: 257
Study: 31037359

Group type: EXPERIMENTAL
Intervention: Parity
Number of subjects: 6500

Group type: EXPERIMENTAL
Intervention: Lactation
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Control (no parity or lactation)
Number of subjects: 6500
Study: 28573932

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR maintained at 1.5 to 2.0) in group A
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard-intensity warfarin (INR maintained at 2.0 to 2.5) in group B
Number of subjects: 101
Study: 24722790

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intermittent pneumatic compression
Number of subjects: 10
Study: 23008110

Group type: EXPERIMENTAL
Intervention: letrozole + tamoxifen and human menopausal gonadotropin (HMG)
Number of subjects: 130

Group type: COMPARATOR
Intervention: placebo instead of tamoxifen
Number of subjects: 130
Study: 21992565

Group type: COMPARATOR
Intervention: Pulmonary autograft (PA) in group 1 (n = 20)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mechanical prosthesis (MP) in group 1 (n = 20)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Stentless bioprosthesis (CE Prima Plus) in group 2 (n = 20)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mechanical prosthesis (MP) in group 2 (n = 20)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Stentless bioprosthesis (CE Prima Plus) in group 3 (n = 20)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Stented bioprosthesis (CE Perimount) in group 3 (n = 20)
Number of subjects: 120
Study: 18608419

Group type: EXPERIMENTAL
Intervention: Physiotherapy interventions
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study: 17598506

Group type: EXPERIMENTAL
Intervention: Prophylactic vaccines for primary prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV DNA tests for secondary prevention
Number of subjects: 0
Study: 15076015

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg for 2 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Automated telephoned questionnaires
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pencil-and-paper questionnaires
Number of subjects: 38
Study: 11696073

Group type: EXPERIMENTAL
Intervention: 300 mg slow-release caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9566820

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: NS5 reactivity
Number of subjects: 103
Study: 7930153

Group type: EXPERIMENTAL
Intervention: District co-ordinating service for terminal care
Number of subjects: 0
Study: 3276409

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (IVSK)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 368
Study: 30599145

Group type: EXPERIMENTAL
Intervention: Targeted Auditory Training (TAT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Computer Games (CG)
Number of subjects: 49
Study: 30265194

Group type: EXPERIMENTAL
Intervention: Clinical decision rule based on major and minor criteria for predicting intracranial hypertension (ICP).
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Clinical decision rule with higher ICP cutoffs.
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Clinical decision rule validated in North American cohort.
Number of subjects: 281
Study: 26320523

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg intravenously + Metoclopramide 10 mg intravenously
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo + Metoclopramide 10 mg intravenously
Number of subjects: 208
Study: 24119192

Group type: EXPERIMENTAL
Intervention: Initial Restrictive Pressure (IRP) of 40-45 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial Restrictive Pressure (IRP) of 60-65 mmHg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22665541

Group type: EXPERIMENTAL
Intervention: Bevacizumab added to gemcitabine/cisplatin
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo with gemcitabine/cisplatin
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Higher pretreatment plasma VEGF concentration
Number of subjects: 115
Study: 18951860

Group type: EXPERIMENTAL
Intervention: Lidocaine patch (LP) applied on the anterior abdominal wall
Number of subjects: 30

Group type: COMPARATOR
Intervention: No lidocaine patch applied
Number of subjects: 30
Study: 17574644

Group type: EXPERIMENTAL
Intervention: Flickering dots presented at 4 degrees eccentricity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flickering dots presented at 14 degrees eccentricity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upper visual field presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower visual field presentation
Number of subjects: 0
Study: 16128595

Group type: EXPERIMENTAL
Intervention: 50 mg/mL oral suspension
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 200mg tablets
Number of subjects: 18

Group type: COMPARATOR
Intervention: 800mg tablets (reference)
Number of subjects: 18
Study: 12081991

Group type: EXPERIMENTAL
Intervention: Stenting plus abciximab
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stenting alone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (non-PCI vessel)
Number of subjects: 48
Study: 9620330

Group type: EXPERIMENTAL
Intervention: Transarterial embolization (TAE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 80
Study: 7666704

Group type: EXPERIMENTAL
Intervention: Problem-solving counseling
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Phone call support
Number of subjects: 293

Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 293
Study: 2571114

Group type: EXPERIMENTAL
Intervention: Dipivefrin hydrochloride 0.1% twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fellow eyes (control group)
Number of subjects: 32
Study: 15848620

Group type: EXPERIMENTAL
Intervention: Double-J stent (DJS) placed during Lich-Gregoir ureterocystotomy
Number of subjects: 42

Group type: COMPARATOR
Intervention: No DJS insertion during Lich-Gregoir ureterostomy
Number of subjects: 42
Study: 31654580

Group type: EXPERIMENTAL
Intervention: Bar implant overdentures (BOD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resilient telescopic implant overdentures (TOD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stud implant overdentures (SOD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clenching hard food
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clenching side (ch2)
Number of subjects: 24
Study: 31586772

Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg administered 1 hour before bedtime for 12 weeks
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo administered 1 hour before bedtime for 12 weeks
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 28342282

Group type: EXPERIMENTAL
Intervention: Immediate-release tacrolimus (IR-TAC)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Extended-release tacrolimus (ER-TAC)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA)
Number of subjects: 23
Study: 25778997

Group type: EXPERIMENTAL
Intervention: Removal of the tensor tympani muscle tendon (group 1)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Retention of the tensor tympani muscle tendon (group 2)
Number of subjects: 212
Study: 23242431

Group type: EXPERIMENTAL
Intervention: Intervention group (fracture clinic initiated assessment)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (GP initiated assessment)
Number of subjects: 66
Study: 21777634

Group type: EXPERIMENTAL
Intervention: Low viscous alginate fibre‐based preloads of 3% concentration (500 ml volume) three times a day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (calorie-restricted diet without alginate preloads)
Number of subjects: 24
Study: 17980952

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN) vaginal gel 80 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal gel 200 microg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Dilapan-S (hygroscopical cervical dilator)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Dilapan-S
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: ISMN
Number of subjects: 65
Study: 16894289

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined-modality therapy (chemotherapy + radiotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy including gemcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positron emission tomography after one or two cycles of chemotherapy
Number of subjects: 0
Study: 12660125

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-based product (0.3% concentration); rinsed three times a day for 30s from the beginning of chemotherapy until the end of leukopenia
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (amine-stannous fluoride combination); rinsed three times a day for 30s from the beginning of chemotherapy until the end of leukopenia
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-based product (0.3% concentration); separate analysis for patients with <1000 leucocytes/microL for a minimum of three days
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (amine-stannous fluoride combination); separate analysis for patients with <1000 leucocytes/microL for a minimum of three days
Number of subjects: 47
Study: 10773060

Group type: EXPERIMENTAL
Intervention: Uninfected exposed hemophiliacs
Number of subjects: 7

Group type: COMPARATOR
Intervention: Infected hemophiliacs
Number of subjects: 7

Group type: COMPARATOR
Intervention: Healthy donors (controls)
Number of subjects: 7
Study: 9361936

Group type: EXPERIMENTAL
Intervention: CMVIG prophylaxis
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 1469516

Group type: EXPERIMENTAL
Intervention: Powdered fortifier (PF)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Liquid supplement (LS)
Number of subjects: 35
Study: 3847401

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (H2O2) instillation in drainage bags
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no H2O2 instillation)
Number of subjects: 0
Study: 31978580

Group type: EXPERIMENTAL
Intervention: Levofloxacin (LFX) resistant isolates from 2005 and 2015
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Levofloxacin (LFX) resistance in 2015
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Mutations in codon 90 of the gyrA gene
Number of subjects: 542
Study: 29468748

Group type: EXPERIMENTAL
Intervention: Test diet (0.8 g protein kg‐1 body weight: 35% animal proteins, 35% soy protein, 30% vegetable proteins)
Number of subjects: 60
Study: 27763459

Group type: EXPERIMENTAL
Intervention: Individual intervention for smoking cessation
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Group-based intervention for smoking cessation
Number of subjects: 400

Group type: COMPARATOR
Intervention: Both interventions (individual and group-based)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Greater attendance in sessions
Number of subjects: 400
Study: 24755713

Group type: EXPERIMENTAL
Intervention: Integrated (INT) risk education protocol
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Disease-specific (DSE) risk education protocol
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 530

Group type: COMPARATOR
Intervention: INT group
Number of subjects: 530

Group type: COMPARATOR
Intervention: DSE group
Number of subjects: 530
Study: 22536597

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acid-etch-and-rinse adhesive system
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (unbleached teeth)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Delayed group (DG)
Number of subjects: 90
Study: 19842609

Group type: EXPERIMENTAL
Intervention: Limbal relaxing incision (LRI) combined with bimanual microincision cataract surgery (MICS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bimanual microincision cataract surgery (MICS) without LRI (non-LRI group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limbal relaxing incision (LRI) combined with bimanual MICS
Number of subjects: 0
Study: 18277214

Group type: EXPERIMENTAL
Intervention: Hemiplegia rehabilitation program with analgesic and calcitonin therapy, elevation, range of movement therapy, and contrast baths.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hemiplegia rehabilitation program without additional therapies (control group).
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (study and control) regarding Ashworth scale.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Between-group comparison for MAS ULF, MAS HM, and MAS AHA.
Number of subjects: 80
Study: 15689289

Group type: EXPERIMENTAL
Intervention: Amoxicillin for 10 days
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 135
Study: 17986534

Group type: EXPERIMENTAL
Intervention: Carex disconnect system
Number of subjects: 363

Group type: COMPARATOR
Intervention: Ultra disconnect system
Number of subjects: 363
Study: 11078235

Group type: EXPERIMENTAL
Intervention: 60% CHO diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: 40% CHO diet
Number of subjects: 8
Study: 8653989

Group type: EXPERIMENTAL
Intervention: Phenobarbital (100 mg/day for 16 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1576053

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 0
Study: 6362999

Group type: EXPERIMENTAL
Intervention: Postoperative intermittent positive pressure breathing (IPPB) for four days with physiotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postoperative care without IPPB
Number of subjects: 30
Study: 31829237

Group type: EXPERIMENTAL
Intervention: specialist palliative care consultation
Number of subjects: 236

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 236
Study: 29183956

Group type: EXPERIMENTAL
Intervention: Crowdsourced video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health marketing video
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPSW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G-formula
Number of subjects: 0
Study: 27061740

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (INT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 152
Study: 25301015

Group type: EXPERIMENTAL
Intervention: Uniform luminous background during the retention interval of the visual working memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased background luminance during imagery generation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal number working memory task
Number of subjects: 0
Study: 22386382

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 28

Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 28
Study: 20855823

Group type: EXPERIMENTAL
Intervention: mGEMOX (gemcitabine 900 mg/m2 and oxaliplatin 80 mg/m2 IV infusion on days 1 and 8 every 3 weeks for maximum of six cycles)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: FUFA (fluorouracil 425 mg/m2 and folinic acid 20 mg/m2 IV bolus weekly for 30 weeks)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 81
Study: 17912635

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg once daily for 5 years
Number of subjects: 5187

Group type: COMPARATOR
Intervention: Letrozole after unblinding
Number of subjects: 5187

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 5187
Study: 16376645

Group type: EXPERIMENTAL
Intervention: Antioxidant supplements
Number of subjects: 312

Group type: COMPARATOR
Intervention: No antioxidant supplements
Number of subjects: 312
Study: 12197366

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Continuous combined hormone replacement therapy (ccHRT)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 1008
Study: 10729965

Group type: EXPERIMENTAL
Intervention: Exercise in combination with manual lymph drainage
Number of subjects: 35

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 35
Study: 9127079

Group type: EXPERIMENTAL
Intervention: Intra-articular instillation of 20 mL bupivacaine (0.25%) and local infiltration of 20 mL bupivacaine (0.5%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline solution injection
Number of subjects: 40
Study: 1436589

Group type: EXPERIMENTAL
Intervention: Defibrotide, 400 mg b.i.d. i.m.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Heparin calcium, 5000 IU b.i.d. s.c.
Number of subjects: 47
Study: 3466089

Group type: EXPERIMENTAL
Intervention: Aural toilet
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Ototopical boric acid
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Aminoglycoside solution
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Oral antianaerobic clindamycin
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Parental tuition in aural cleaning, avoidance of ear water entry, nose blowing and breathing
Number of subjects: 3500
Study: 30922377

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 mcg daily for three months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cholecalciferol 1000 IU daily for three months
Number of subjects: 23
Study: 30371299

Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg/d for 24 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 26047775

Group type: EXPERIMENTAL
Intervention: Clinical assessment + GRACE scoring system
Number of subjects: 572

Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: GRACE score >140
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Secondary referral from a non-PCI cardiology department
Number of subjects: 572
Study: 25440794

Group type: EXPERIMENTAL
Intervention: ALDH(br) cells delivered by direct intramuscular injections
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 80
Study: 23140761

Group type: EXPERIMENTAL
Intervention: Resistant starch
Number of subjects: 918

Group type: COMPARATOR
Intervention: Resistant-starch placebo
Number of subjects: 918
Study: 20808210

Group type: EXPERIMENTAL
Intervention: Two-handed jaw-thrust technique
Number of subjects: 42

Group type: COMPARATOR
Intervention: One-handed 'EC-clamp' technique
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Comparison of techniques
Number of subjects: 42
Study: 18958560

Group type: EXPERIMENTAL
Intervention: 80 mg/m2 paclitaxel administered weekly
Number of subjects: 68
Study: 15908042

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy (mitomycin, ifosfamide and cisplatin (MIC) or mitomycin, vinblastine and cisplatin (MVP)) followed by surgery (CT-S)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Radical radiotherapy (RT)
Number of subjects: 48
Study: 11796917

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Marrow in vitro purging with mafosfamide
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy post-ASCT
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: ASCT
Number of subjects: 1635
Study: 10615229

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2 every 3 weeks, n = 143)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Sequential methotrexate and 5-fluorouracil (MF; 200 mg/m2 and 600 mg/m2 every 3 weeks, n = 139)
Number of subjects: 283